CN104043125B - 诱导肿瘤缺氧以治疗癌症 - Google Patents

诱导肿瘤缺氧以治疗癌症 Download PDF

Info

Publication number
CN104043125B
CN104043125B CN201310699012.3A CN201310699012A CN104043125B CN 104043125 B CN104043125 B CN 104043125B CN 201310699012 A CN201310699012 A CN 201310699012A CN 104043125 B CN104043125 B CN 104043125B
Authority
CN
China
Prior art keywords
tumor
tirapazamine
hypoxemia
stilbene
hypoxia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310699012.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN104043125A (zh
Inventor
李瑞民
林柏孙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Original Assignee
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University filed Critical Virginia Commonwealth University
Publication of CN104043125A publication Critical patent/CN104043125A/zh
Application granted granted Critical
Publication of CN104043125B publication Critical patent/CN104043125B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201310699012.3A 2008-04-10 2009-04-08 诱导肿瘤缺氧以治疗癌症 Active CN104043125B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4396408P 2008-04-10 2008-04-10
US61/043,964 2008-04-10
CN200980102782.7A CN102026634B (zh) 2008-04-10 2009-04-08 诱导肿瘤缺氧以治疗癌症

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200980102782.7A Division CN102026634B (zh) 2008-04-10 2009-04-08 诱导肿瘤缺氧以治疗癌症

Publications (2)

Publication Number Publication Date
CN104043125A CN104043125A (zh) 2014-09-17
CN104043125B true CN104043125B (zh) 2018-01-12

Family

ID=41162569

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310699012.3A Active CN104043125B (zh) 2008-04-10 2009-04-08 诱导肿瘤缺氧以治疗癌症
CN200980102782.7A Active CN102026634B (zh) 2008-04-10 2009-04-08 诱导肿瘤缺氧以治疗癌症

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200980102782.7A Active CN102026634B (zh) 2008-04-10 2009-04-08 诱导肿瘤缺氧以治疗癌症

Country Status (6)

Country Link
US (4) US8591921B2 (https=)
JP (2) JP5731372B2 (https=)
KR (1) KR101925436B1 (https=)
CN (2) CN104043125B (https=)
TW (1) TWI504391B (https=)
WO (1) WO2009126705A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2592103Y2 (ja) 1992-07-23 1999-03-17 東海旅客鉄道株式会社 ケーブルトラフ
EP1896040B1 (en) 2005-06-29 2012-08-01 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
CN104043125B (zh) 2008-04-10 2018-01-12 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症
ES2877629T3 (es) * 2010-07-12 2021-11-17 Immunogenesis Inc Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
EP2407161A1 (en) * 2010-07-13 2012-01-18 Sanofi An antitumoral combination comprising ombrabulin and bevacizumab
US9402820B2 (en) 2011-04-22 2016-08-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of pyruvate or succinate to enhance the efficacy of a hypoxia activated prodrug for the treatment of tumors
EP2793882A4 (en) 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
CN102512692B (zh) * 2012-01-16 2014-07-16 北京大学 肿瘤靶向栓塞治疗组合物及其制备方法
AU2013204313C1 (en) * 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
WO2015069489A1 (en) 2013-11-06 2015-05-14 Merck Patent Gmbh Predictive biomarker for hypoxia-activated prodrug therapy
US10172815B2 (en) * 2013-11-11 2019-01-08 University Hospitals Cleveland Medical Center Targeted treatment of anerobic cancer
US9586056B2 (en) * 2014-07-03 2017-03-07 Haniva Llc Combination therapy for treating cancer and method for treating cancer using a combination therapy
ES2822557T3 (es) * 2014-08-08 2021-05-04 Poseida Therapeutics Inc Composiciones y su uso para inducir la embolización microvascular de tumores mediada por nanopartículas
EP4548978A3 (en) 2015-01-29 2025-08-06 Oxyrase, Inc. Methods for inhibiting tumor growth
EP3294313A4 (en) * 2015-05-15 2019-04-17 The General Hospital Corporation METHODS RELATING TO THE PREVENTION AND TREATMENT OF DRUG RESISTANCE
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
WO2017070606A1 (en) * 2015-10-21 2017-04-27 Teclison Limited Compositions and methods for immune-mediated cancer therapy
US11213594B2 (en) 2016-04-29 2022-01-04 Poseida Therapeutics, Inc. Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids
JP2019515011A (ja) * 2016-05-13 2019-06-06 テクリソン リミテッド 肝臓組織を処置するための方法
CN107007571B (zh) * 2017-02-24 2020-08-21 福州市传染病医院 肿瘤微酸性敏感的铜-药物共配位自组装纳米粒及应用
CN110051848A (zh) * 2019-05-06 2019-07-26 中国科学院长春应用化学研究所 药物组合、应用以及抗肿瘤的药物
CN110585214A (zh) * 2019-09-25 2019-12-20 湖北大学 一种促进治疗肿瘤效果的纳米粒子及其合成方法
CN110713596B (zh) * 2019-11-08 2022-04-29 西北师范大学 肿瘤无导管栓塞用pH-还原双响应高分子栓塞剂及其合成
CN112961082B (zh) * 2021-02-22 2022-09-06 沈阳药科大学 一种血管阻断剂与双载药仿生脂质体联用的给药系统
JP7730130B2 (ja) * 2021-03-02 2025-08-27 ドリームメディカルパートナーズ株式会社 塞栓材及びその製造方法
US20250302394A1 (en) * 2021-09-22 2025-10-02 Board Of Regents, The University Of Texas System Quantitative magnetic resonance imaging and tumor forecasting
CN114344482B (zh) * 2022-01-14 2023-05-12 重庆医科大学附属第二医院 一种基于金属有机骨架的多功能纳米粒及其制备方法与应用
WO2024006901A1 (en) * 2022-06-29 2024-01-04 Diffusion Pharmaceuticals Llc Uses of bipolar trans carotenoids in the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202352A (en) * 1990-08-08 1993-04-13 Takeda Chemical Industries, Ltd. Intravascular embolizing agent containing angiogenesis-inhibiting substance

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980779A (en) 1972-02-01 1976-09-14 Bayer Aktiengesellschaft 3-Amino-1,2,4-benzotriazine-1,4-di-N-oxide compositions and method of using same
US5616584A (en) 1986-09-25 1997-04-01 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
US5175287A (en) 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
CA2472404A1 (en) 1993-07-19 1995-02-02 Angiotech Pharmaceuticals, Inc. Combination of stent and anti-angiogenic factor
US5484612A (en) 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
GB9404400D0 (en) 1994-03-07 1994-04-20 Wood Pauline J Potentiation of bioreductive agents
EP1014990B1 (en) 1997-03-07 2006-09-06 Sanofi-Aventis U.S. LLC Antitumor combination of 3-amino-1,2,4-benzotriazine 1,4-dioxide/paclitaxel/platinum
DE10012120A1 (de) 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
CN1555253A (zh) * 2001-09-13 2004-12-15 ������ѧ�����о�Ժ 化疗栓塞用紫杉醇的油性组合物、制剂及它们的制造方法
EP1599196A4 (en) * 2003-01-17 2006-05-31 Threshold Pharmaceuticals Inc COMBINATION THERAPIES FOR CANCER TREATMENT
US20060264388A1 (en) 2003-02-26 2006-11-23 Olga Valota Method for treating liver cancer by intrahepatic administration of nemorubicin
ITRM20030355A1 (it) 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Composti ad attivita' citotossica derivati della combretastatina.
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
CN104043125B (zh) 2008-04-10 2018-01-12 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202352A (en) * 1990-08-08 1993-04-13 Takeda Chemical Industries, Ltd. Intravascular embolizing agent containing angiogenesis-inhibiting substance

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment,with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells;SHIN-ICHIRO MASUNAGA et al;《ONCOLOGY REPORTS》;20051231;第14卷;摘要 *
Low-Dose Metronomic Daily Cyclophosphamide and Weekly Tirapazamine: A Well-Tolerated Combination Regimen with Enhanced Efficacy That Exploits Tumor Hypoxia;Urban Emmenegger et al;《Cancer Res》;20060201;第66卷(第3期);摘要 *

Also Published As

Publication number Publication date
KR20110050583A (ko) 2011-05-16
JP5731372B2 (ja) 2015-06-10
TW201002312A (en) 2010-01-16
KR101925436B1 (ko) 2018-12-05
CN102026634B (zh) 2014-01-22
CN102026634A (zh) 2011-04-20
WO2009126705A8 (en) 2011-04-14
TWI504391B (zh) 2015-10-21
US8591921B2 (en) 2013-11-26
WO2009126705A3 (en) 2010-02-18
US20120087913A1 (en) 2012-04-12
JP5944018B2 (ja) 2016-07-05
JP2011516565A (ja) 2011-05-26
HK1202057A1 (en) 2015-09-18
US20180050039A1 (en) 2018-02-22
US20140065139A1 (en) 2014-03-06
CN104043125A (zh) 2014-09-17
JP2015110602A (ja) 2015-06-18
US10159676B2 (en) 2018-12-25
WO2009126705A2 (en) 2009-10-15
US10426779B2 (en) 2019-10-01
US9649316B2 (en) 2017-05-16
US20170224693A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
CN104043125B (zh) 诱导肿瘤缺氧以治疗癌症
Ishida et al. MRI-guided focused ultrasound enhances drug delivery in experimental diffuse intrinsic pontine glioma
Miller et al. Poly (ethylene glycol)–paclitaxel–alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases
Teicher et al. Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in human T98G glioblastoma multiforme xenografts
US11931423B2 (en) Glucose oxidase-nanoparticle bioconjugates for cancer treatment
US20160324829A1 (en) Combination therapy with parp inhibitors
Appelbe et al. Image-guided radiotherapy targets macromolecules through altering the tumor microenvironment
Berghoff et al. Role of the blood–brain barrier in metastatic disease of the central nervous system
US20130225647A1 (en) Combination therapy with parp inhibitors
JP2024538364A (ja) ニロガセスタットを用いた組成物及び治療
CN110062633A (zh) 酪氨酸衍生物以及包含所述酪氨酸衍生物的组合物
US8545841B2 (en) Methods and compositions for the treatment of cancers and pathogenic infections
WO2026061436A1 (zh) 泮托拉唑在制备msln-car-t细胞治疗脑转移瘤的增强剂中的应用
US20210169903A1 (en) Pharmaceutical compositions and methods
US20100035952A1 (en) Radiosensitizer Formulations and Methods for Use
Brem Angiogenesis antagonists: current clinical trials
HK1202057B (en) Induction of tumor hypoxia for cancer therapy
Sethi et al. Ipid nanomedicine simultaneously inhibits BRD4/PI3K and MDM2/XIAP signaling pathways for effective treatment of Medulloblastoma
JP2004521929A (ja) イソクマリン誘導体を使用する腫瘍の放射線増感および／または化学相乗作用
Kosaka et al. 546: Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Prostate Cancer
Kawai et al. 547: Suppression of the Prostate Tumor Growth and Bone Destruction in the Bone Microenvironment by Heat Therapy with Magnetic Nano-Particle Conjugated with Cationic Liposome
JP2010507628A (ja) 骨ガンの処置又は予防のためのｍｔｋｉ１の使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent for invention or patent application
CB03 Change of inventor or designer information

Inventor after: Li Ruimin

Inventor after: Lin Baisun

Inventor before: Li Ruimin

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: LI RUIMIN TO: LI RUIMIN LIN BAISUN

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1202057

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1202057

Country of ref document: HK